[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"meningioma-of-brain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:meningioma-of-brain":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100625141","tumor-genomics-individual-risk-factors-and-external-drivers-of-health-on-health-outcomes-for-patients-with-meningioma-100625141",false,"NCT07418775","Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma","An Investigation of Tumor Genomics, Individual Risk Factors, and External Drivers of Health to Improve Health Outcomes for Patients With Meningioma","Inclusion Criteria:\n\n* Adults ≥18 years of age\n* Able to speak and read English\n* Diagnosed with a meningioma\n\nExclusion Criteria:\n\n* Active psychiatric issues (suicidality, active psychosis, grave disability, etc.)\n* Inability to consent secondary to severe neurologic deficit or psychiatric distress\n* Inability to complete survey secondary to severe neurologic deficit or psychiatric distress",true,"ALL","18 Years",{"count":20,"type":21},3000,"ESTIMATED","OBSERVATIONAL","Meningiomas are the most common primary brain tumor, and some groups are diagnosed with higher-grade tumors and have clinically worse outcomes. This study investigates social determinants of health and individual risk factors that may be associated with meningioma.",[25,26,27],"Meningioma of Brain","Meningioma","Brain Tumor","RECRUITING","2026-05-15",{"date":31,"type":32},"2026-05-19","ACTUAL",{"date":34,"type":32},"2026-01-16",{"date":36,"type":21},"2032-01-01",{"name":38,"class":39},"University of California, San Francisco","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100614659","epigenetic-profiling-and-liquid-biopsy-perspectives-for-personalized-medicine-in-meningioma-patients---mind-100614659","NCT07282470","Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND","Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients","MIND","Inclusion Criteria:\n\nInclusion Criteria (Retrospective \\& Prospective):\n\n* Patient aged 18 years or older.\n* First diagnosis of uni-focal meningioma of the convexity.\n* Macroscopical total resection (Simpson 1-3).\n\n(Retrospective only):\n\n* Surgery performed between 2007 and 2016;\n* availability of FFPE sample and medical records.\n\nExclusion Criteria:\n\n* Genetic syndromes.\n* Diffuse Meningeal Meningiomatosis.\n* Patients who underwent experimental treatment in neo-adjuvant setting.\n\n(Prospective only):\n\n* Previous surgical\u002Fmedical treatment for another meningioma;\n* positive oncological history (e.g., breast cancer).",{"count":50,"type":21},210,"Meningiomas are the most common primary intracranial tumors. Current treatment relies on surgical resection and radiotherapy, but molecular predictors for recurrence are lacking. This study aims to investigate epigenetic features, specifically histone post-translational modifications (PTMs) and DNA methylation, to stratify patients. The study involves a retrospective cohort to define an epigenetic signature and a prospective cohort to validate it in tissues and liquid biopsies (plasma\u002FEVs).",[26,25],[26,54],"Machine Learning","2026-02-09",{"date":57,"type":32},"2026-02-10",{"date":59,"type":32},"2024-09-25",{"date":61,"type":21},"2026-03",{"name":63,"class":39},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta"]